Antoni Martínez-Rubio

Antoni Martínez-Rubio

FESC MD FACC PhD

University Hospital of Sabadell, Sabadell, ES

  • OrcidID

Research areas

Atrial Fibrillation

Coronary Artery Disease and Myocardial Infarction

Biography

Dr Antoni Martinez Rubio , Jefe de Servicio de Cardiología del Hospital Parc Taulí de Sabadell (Barcelona, España).

Dr Martínez-Rubio is on the Editorial Board of European Cardiology Review.

Read more

Media

Pablo Avanzas, Román Freixa Pamias, Antoni Martínez-Rubio, et al

Watch time: 28m 4s
Esc 2015: Assessing Risk of Bleeding in Patients Who Require New Oral Anticoagulants

Antoni Martínez-Rubio

Watch time: 4m 9s

Articles by Antoni Martínez-Rubio

Oral Anticoagulation and Prognosis of Patients with Atrial Fibrillation After Ischemic Stroke: A Real-world Data Analysis

Mario DiazNuila-Alcazar, Daniel Valcárcel-Paz, Pablo Del Castillo-Vásquez, et al

Citation: European Cardiology Review 2017;12(2):95.

DOI:

https://doi.org/10.15420/ecr.2017:23:3
Evidence-based Management of Left Main Coronary Artery Disease

Gabriel Torres-Ruiz, Nuria Mallofré-Vila, Paola Rojas-Flores, et al

Published:

Citation: European Cardiology Review 2023;18:e63.

DOI:

https://doi.org/10.15420/ecr.2023.36
Safety of Antiplatelet Pretreatment in Non-ST-segment Elevation Acute Coronary Syndrome

G Torres-Ruiz, P Rojas-Flores, P Carrion Montaner, et al

Published:

Citation: European Cardiology Review 2023;18:e26.

DOI:

https://doi.org/10.15420/ecr.2023.18.PO9
Appropriateness of Antiplatelet Pretreatment in Non-ST-segment Elevation Acute Coronary Syndrome: Differences Between Unstable Angina and Acute Myocardial Infarction

G Torres-Ruiz, P Rojas-Flores, N Mallofré Vila, et al

Published:

Citation: European Cardiology Review 2023;18:e20.

DOI:

https://doi.org/10.15420/ecr.2023.18.PO3
LDL-C Reduction in Diabetic Patients after Percutaneous Coronary Intervention: Is There any Difference with Non-diabetic?

N Mallofré Vila, G Torres-Ruiz, C Roca-Guerrero, et al

Published:

Citation: European Cardiology Review 2023;18:e19.

DOI:

https://doi.org/10.15420/ecr.2023.18.PO2
Coronavirus Disease 2019 and Cardiac Arrhythmias

Antoni Martínez-Rubio, Soledad Ascoeta, Fadwa Taibi, et al

Published:

Citation: European Cardiology Review 2020;15:e66.

DOI:

https://doi.org/10.15420/ecr.2020.23
Prescription of Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction Attending an Outpatient Heart Failure Clinic

M Rizzo, I Colomer-Asenjo, M Sutil-Vega, et al

Citation: European Cardiology Review 2020;15:e31.

DOI:

https://doi.org/10.15420/ecr.2020.15.1.PO8
Tolerability Profile and Discontinuation Causes of Sacubitril/Valsartan Treatment in ‘Real-life’ Patients with Heart Failure and Reduced Ejection Fraction

M Rizzo, I Colomer-Asenjo, G Cabello-Molina, et al

Citation: European Cardiology Review 2020;15:e32.

DOI:

https://doi.org/10.15420/ecr.2020.15.1.PO9
Differences in Clinical Characteristics, Results and Management of Patients Referred for Pharmacologic Cardiac Stress SPECT Depending on the Protocol Used

Pablo Del Castillo-Vásquez, Núria Casanovas, Marcel Santaló-Corcoy, et al

Citation: European Cardiology Review 2017;12(2):102.

DOI:

https://doi.org/10.15420/ecr.2017:23:11
Secondary Prevention in Patients with Non Valvular Atrial Fibrillation and Previous Stroke. Is It Possible to Have an Appropriate INR Control?

Mario DiazNuila-Alcazar, Daniel Valcárcel-Paz, Marcel Santaló-Corcoy, et al

Citation: European Cardiology Review 2017;12(2):103.

DOI:

https://doi.org/10.15420/ecr.2017:23:12
Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation: Assessment, Monitoring and Treatment Reversal

Antoni Martínez-Rubio, Mario DiazNuila-Alcazar, Anna Soria Cadena, et al

Published:

Citation: European Cardiology Review 2016;11(2):118–22

DOI:

https://doi.org/10.15420/ecr.2016:30:1
Cardiovascular Pharmacotherapies Focus: Are low doses of direct-acting oral anticoagulants justified and appropriate in patients with nonvalvular atrial fibrillation?

Antoni Martínez-Rubio, Gheorghe-Andrei Dan,

Citation: European Cardiology Review 2016;11(2):115–7

DOI:

https://doi.org/10.15420/ecr.2016.11.2.ED2
Key Recent Advances in Atherosclerosis Treatment with Modern Lipid-lowering Drugs: The New Frontier with PCSK9 Inhibitors

Antoni Martínez-Rubio, Román Freixa Pamias,

Citation: European Cardiology Review 2017;12(1):30–2

DOI:

https://doi.org/10.15420/ecr.2017.12.1.GE3